|
Mutation Information
|
Mutation Site
|
N160K |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
Gp120 |
|
Country
|
US |
Literature Information
|
PubMed PMID
|
32156815
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2020 |
|
Journal
|
mBio |
|
Title
|
Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants. |
|
Author
|
Martinez DR,Tu JJ,Kumar A,Mangold JF,Mangan RJ,Goswami R,Giorgi EE,Chen J,Mengual M,Douglas AO,Heimsath H,Saunders KO,Nicely NI,Eudailey J,Hernandez G,Morgan-Asiedu PK,Wiehe K,Haynes BF,Moody MA,LaBranche C,Montefiori DC,Gao F,Permar SR |
|
Evidence
|
We failed to detect a reduction in the neutralization activity against BJOX2000 N160K, BJOX2000 N332A, TRO.11 N276Q, TRO.11 N279A, TRO.11 G458Y, Ce1176 N88A, and Ce1176 N625A mutants compared to the neutralization activity against wild-type BJOX2000, TRO.11, and Ce1176 viruses in nontransmitting woman 0301 or transmitting woman 3902, suggesting the absence of V2 glycan-targeting, V3 glycan-targeting, CD4 binding site-targeting, and gp120/gp41 interface glycan-targeting plasma bNAb responses (Fig. 3B; see also Fig. S6).
|
|
|
HIV Mutation Detail Information